CollPlant Biotechnologies Ltd.
CLGN
$2.29
-$0.1295-5.35%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -93.61% | 1,495.20% | 3,565.22% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -93.61% | 1,495.20% | 3,565.22% | |
| Cost of Revenue | -- | 68.40% | 218.59% | 397.75% | |
| Gross Profit | -- | -115.16% | 30,146.43% | 8,979.21% | |
| SG&A Expenses | -- | -5.66% | -11.30% | -11.05% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | 7.45% | 8.18% | 6.18% | |
| Operating Income | -- | -163.46% | 50.61% | 56.06% | |
| Income Before Tax | -- | -159.48% | 55.31% | 58.53% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -159.48% | 55.31% | 58.53% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -159.48% | 55.31% | 58.53% | |
| EBIT | -- | -163.46% | 50.61% | 56.06% | |
| EBITDA | -- | -195.11% | 54.11% | 59.99% | |
| EPS Basic | -- | -149.42% | 56.72% | 59.91% | |
| Normalized Basic EPS | -- | -787.82% | 112.48% | 112.48% | |
| EPS Diluted | -- | -143.00% | 55.72% | 58.94% | |
| Normalized Diluted EPS | -- | -914.77% | 110.23% | 110.23% | |
| Average Basic Shares Outstanding | -- | 2.01% | 2.47% | 3.19% | |
| Average Diluted Shares Outstanding | -- | 1.09% | 3.38% | 4.11% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |